Failure free survival following brachytherapy alone for prostate cancer: Comparison with external beam radiotherapy

Radiotherapy and Oncology

Volumn 57, Issue 3, 2000, Pages 263-267

  Beyer, David C ^a   Brachman, David G ^b  

^a Arizona Oncology Services   (United States)

^b Foundation for Cancer Research and Education   (United States)

Author keywords

Brachytherapy; External beam radiotherapy; Prostate cancer; Survival

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

AGED; BEAM THERAPY; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; ULTRASOUND;

AGED; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 0034562938     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00286-3     Document Type: Conference Paper

References (17)

1. Consensus statement: guidelines for PSA following radiation therapy
2. Biochemical disease-free survival following 125I prostate implantation
3. Five-year tumor recurrence rates after anatomical radical retro-pubic prostatectomy for prostate cancer
4. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localised prostate cancer
5. Histologic grade, clinical stage, and patient age in prostate cancer
6. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions
7. External beam irradiation versus iodine-125 implant in the definitive treatment of prostate carcinoma
8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
9. Localized prostate cancer treatment by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis
10. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection
11. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer
12. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer
13. External beam radiotherapy dose response of prostate cancer
14. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up
15. Tumor control and morbidity following transperineal iodine 125I implantation for stage T1/T2 prostate carcinoma
16. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
17. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer